Top

International Journal of Clinical Oncology

Published in:

01-11-2019 | Endometrial Cancer | Original Article

The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas

Authors: Stylianos Vagios, Petros Yiannou, Elpida Giannikaki, Triada Doulgeraki, Christos Papadimitriou, Alexandros Rodolakis, Afroditi Nonni, Athanassios Vlachos, Kitty Pavlakis

Published in: International Journal of Clinical Oncology | Issue 11/2019

Abstract

Background

To evaluate the expression of programmed cell death-ligand 1 (PD-L1) and CD8 in high-grade endometrial carcinomas and relate it to several clinicopathological parameters.

Methods

One hundred and one (101) patients with high-grade endometrial carcinomas who were completely surgically staged were included in this study. PD-L1 and CD8 + expression was evaluated by immunohistochemistry.

Results

In our cohort, 47 women (46.5%) had endometrioid carcinomas and 54 patients (53.5%) were diagnosed with non-endometrioid cancers. In endometrioid carcinomas, there was a significantly higher rate of positivity for PD-L1 expression (p = 0.042) and of intraepithelial CD8 + cell counts (p = 0.004) as opposed to non-endometrioid cancers. There were no significant relationships with any of the other clinicopathological features under study. Univariate and multivariate analysis revealed that only high intraepithelial CD8 + counts (p = 0.01) was associated with longer progression-free survival. Tumors positive for PD-L1 and high intraepithelial CD8 expression were mainly of endometrioid histology, whilst PD-L1-positive/CD8 low and PD-L1-negative/CD8 low tumors were mostly non-endometrioid carcinomas (p = 0.01). PD-L1 negative/CD8 high tumors had the longest progression-free survival (p = 0.032).

Conclusions

In grade 3 endometrial carcinomas, both of endometrioid and non-endometrioid type, high intraepithelial CD8 + counts represent an independent favorable prognostic factor and when related to PD-L1-negative tumors, a longer progression-free survival can be predicted. Immunotherapy could probably be considered for PD-L1-positive/CD8 + high tumors, which were mostly of endometrioid histology.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289. https://doi.org/10.3322/caac.21349 CrossRefPubMed

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17CrossRefPubMed

Colombo N, Creutzberg C, Amant F et al (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1):16–41. https://doi.org/10.1093/annonc/mdv484 CrossRefPubMed

Suarez AA, Felix AS, Cohn DE (2017) Bokhman redux: endometrial cancer "types" in the 21st century. Gynecol Oncol 144(2):243–249. https://doi.org/10.1016/j.ygyno.2016.12.010 CrossRefPubMed

Piulats JM, Guerra E, Gil-Martin M et al (2017) Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 145(1):200–207. https://doi.org/10.1016/j.ygyno.2016.12.015 CrossRefPubMed

Kondratiev S, Sabo E, Yakirevich E et al (2004) Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10(13):4450–4456. https://doi.org/10.1158/1078-0432.CCR-0732-3 CrossRefPubMed

de Jong RA, Boerma A, Boezen HM et al (2012) Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer 131(8):1828–1836. https://doi.org/10.1002/ijc.27449 CrossRefPubMed

Suemori T, Susumu N, Iwata T et al (2015) Intratumoral CD8+ lymphocyte infiltration as a prognostic factor and its relationship with cyclooxygenase 2 expression and microsatellite instability in endometrial cancer. Int J Gynecol Cancer 25(7):1165–1172. https://doi.org/10.1097/IGC.0000000000000482 CrossRefPubMed

10.

de Jong RA, Leffers N, Boezen HM et al (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114(1):105–110. https://doi.org/10.1016/j.ygyno.2009.03.022 CrossRefPubMed

11.

Iurchenko NP, Glushchenko NM, Buchynska LG (2014) Comprehensive analysis of intratumoral lymphocytes and FOXP3 expression in tumor cells of endometrial cancer. Exp Oncol 36(4):262–266PubMed

12.

Ladanyi A, Somlai B, Gilde K et al (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10(2):521–530CrossRefPubMed

13.

Gadducci A, Guerrieri ME (2017) Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research. Anticancer Res 37(11):5955–5965. https://doi.org/10.21873/anticanres.12042 CrossRefPubMed

14.

Howitt BE, Shukla SA, Sholl LM et al (2015) Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1(9):1319–1323. https://doi.org/10.1001/jamaoncol.2015.2151 CrossRefPubMed

15.

Vanderstraeten A, Luyten C, Verbist G et al (2014) Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 63(6):545–557. https://doi.org/10.1007/s00262-014-1537-8 CrossRefPubMedPubMedCentral

16.

Jones NL, Xiu J, Chatterjee-Paer S et al (2017) Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer 140(6):1396–1404. https://doi.org/10.1002/ijc.30537 CrossRefPubMed

17.

Liu J, Liu Y, Wang W et al (2015) Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med 10(5):1947–1952. https://doi.org/10.3892/etm.2015.2714 CrossRefPubMedPubMedCentral

18.

Asaka S, Yen TT, Wang TL et al (2019) T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol 32(4):576–584. https://doi.org/10.1038/s41379-018-0172-x CrossRefPubMed

19.

Crumley S, Kurnit K, Hudgens C et al (2019) Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol 32(3):396–404. https://doi.org/10.1038/s41379-018-0148-x CrossRefPubMed

20.

Li Z, Joehlin-Price AS, Rhoades J et al (2018) Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency. Int J Gynecol Cancer 28(1):59–68. https://doi.org/10.1097/IGC.0000000000001120 CrossRefPubMed

21.

Bregar A, Deshpande A, Grange C et al (2017) Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol 145(3):446–452. https://doi.org/10.1016/j.ygyno.2017.03.006 CrossRefPubMed

22.

Sungu N, Yildirim M, Desdicioglu R et al (2018) Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer. Int J Gynecol Pathol. https://doi.org/10.1097/PGP.0000000000000543 CrossRef

23.

Tawadros AIF, Khalafalla MMM (2018) Expression of programmed death-ligand 1 and hypoxia-inducible factor-1alpha proteins in endometrial carcinoma. J Cancer Res Ther 14(Supplement):S1063–S1069. https://doi.org/10.4103/0973-1482.202891 CrossRefPubMed

24.

Kim J, Kim S, Lee HS et al (2018) Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecol Oncol 149(2):381–387. https://doi.org/10.1016/j.ygyno.2018.02.013 CrossRefPubMed

25.

Yamashita H, Nakayama K, Ishikawa M et al (2018) Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget 9(5):5652–5664. https://doi.org/10.18632/oncotarget.23790 CrossRefPubMed

26.

Thallinger C, Fureder T, Preusser M et al (2018) Review of cancer treatment with immune checkpoint inhibitors: current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr 130(3–4):85–91. https://doi.org/10.1007/s00508-017-1285-9 CrossRefPubMed

27.

Mittica G, Ghisoni E, Giannone G et al (2017) Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 8(52):90532–90544. https://doi.org/10.18632/oncotarget.20042 CrossRefPubMedPubMedCentral

28.

US Food and Drug Administration (2017) FDA approves first cancer treatment for any solid tumor with a specific genetic feature. US Food and Drug Administration, Silver Spring

29.

De Felice F, Marchetti C, Tombolini V et al (2019) Immune check-point in endometrial cancer. Int J Clin Oncol. https://doi.org/10.1007/s10147-019-01437-7 CrossRefPubMed

30.

Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954 CrossRefPubMedPubMedCentral

31.

Eggink FA, Van Gool IC, Leary A et al (2017) Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 6(2):e1264565. https://doi.org/10.1080/2162402X.2016.1264565 CrossRefPubMed

32.

Ott PA, Bang YJ, Berton-Rigaud D et al (2017) Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 35(22):2535–2541. https://doi.org/10.1200/JCO.2017.72.5952 CrossRefPubMed

33.

Kraft S, Fernandez-Figueras MT, Richarz NA et al (2017) PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. J Am Acad Dermatol 77(3):534–542. https://doi.org/10.1016/j.jaad.2017.05.007 CrossRefPubMed

34.

Teng MW, Ngiow SF, Ribas A et al (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145. https://doi.org/10.1158/0008-5472.CAN-15-0255 CrossRefPubMedPubMedCentral

35.

Husseinzadeh N, Husseinzadeh HD (2014) mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol 133(2):375–381. https://doi.org/10.1016/j.ygyno.2014.02.017 CrossRefPubMed

36.

Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237–251. https://doi.org/10.1038/nrc3237 CrossRefPubMedPubMedCentral

37.

Santin AD, Bellone S, Buza N et al (2016) Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 22(23):5682–5687. https://doi.org/10.1158/1078-0432.CCR-16-1031 CrossRefPubMedPubMedCentral

38.

Mehnert JM, Panda A, Zhong H et al (2016) Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Investig 126(6):2334–2340. https://doi.org/10.1172/JCI84940 CrossRefPubMedPubMedCentral

39.

Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824 CrossRefPubMed

40.

Sabatier R, Finetti P, Mamessier E et al (2015) Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 6(7):5449–5464. https://doi.org/10.18632/oncotarget.3216 CrossRefPubMed

41.

Tamura T, Ohira M, Tanaka H et al (2015) Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res 35(10):5369–5376PubMed

42.

Mo Z, Liu J, Zhang Q et al (2016) Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett 12(2):944–950. https://doi.org/10.3892/ol.2016.4744 CrossRefPubMedPubMedCentral

43.

Bellone S, Bignotti E, Lonardi S et al (2017) Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol 144(1):146–152. https://doi.org/10.1016/j.ygyno.2016.11.023 CrossRefPubMed

44.

Fridman WH, Pages F, Sautes-Fridman C et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. https://doi.org/10.1038/nrc3245 CrossRefPubMed

45.

Cermakova P, Melichar B, Tomsova M et al (2014) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res 34(10):5555–5561PubMed

46.

Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235–251. https://doi.org/10.1097/PAP.0000000000000162 CrossRefPubMedPubMedCentral

47.

Thompson ED, Zahurak M, Murphy A et al (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66(5):794–801. https://doi.org/10.1136/gutjnl-2015-310839 CrossRefPubMed

48.

Al-Shibli KI, Donnem T, Al-Saad S et al (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14(16):5220–5227. https://doi.org/10.1158/1078-0432.CCR-08-0133 CrossRefPubMed

49.

Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335. https://doi.org/10.1097/PAP.0000000000000161 CrossRefPubMedPubMedCentral

50.

Jung IK, Kim SS, Suh DS et al (2014) Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma. Obstet Gynecol Sci 57(4):266–273. https://doi.org/10.5468/ogs.2014.57.4.266 CrossRefPubMedPubMedCentral

51.

Wang Q, Lou W, Di W et al (2017) Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol 52:7–14. https://doi.org/10.1016/j.intimp.2017.08.017 CrossRefPubMed

Title: The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas
Authors: Stylianos Vagios
Petros Yiannou
Elpida Giannikaki
Triada Doulgeraki
Christos Papadimitriou
Alexandros Rodolakis
Afroditi Nonni
Athanassios Vlachos
Kitty Pavlakis
Publication date: 01-11-2019
Publisher: Springer Singapore
Keywords: Endometrial Cancer
Endometrial Cancer
Published in: International Journal of Clinical Oncology / Issue 11/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01484-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Development and validation of a nomogram containing the prognostic determinants of chondrosarcoma based on the Surveillance, Epidemiology, and End Results database

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis

Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials

Including positive lymph node count in the AJCC N staging may be a better predictor of the prognosis of NSCLC patients, especially stage III patients: a large population-based study

Pro-gastrin-releasing peptide as a marker for the Ewing sarcoma family of tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer